Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Raymond James Upgrades Xencor, Inc. (XNCR) to Outperform
February 24, 2021 6:56 AM ESTRaymond James analyst Dane Leone upgraded Xencor, Inc. (NASDAQ: XNCR) from Market Perform to Outperform with a price target of $58.00.
The analyst comments "We are upgrading our recommendation of Xencor from Market Perform to Outperform and establishing a $58 price target. Our thesis is... More
Xencor (XNCR) Tops Q4 EPS by 14c, Revenues Beat
February 23, 2021 4:03 PM ESTXencor (NASDAQ: XNCR) reported Q4 EPS of ($0.24), $0.14 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $41.85 million versus the consensus estimate of $29.46 million.
"Throughout 2020, we advanced multiple clinical programs, introduced several new XmAb® bispecific technologies, and saw the progress of many partnered programs, including U.S. regulatory approval for tafasitamab, the second antibody with XmAb technology to achieve commercialization. Internally, early-stage clinical data have guided our decisions to advance several... More
